SCHEMBL13385495

SCHEMBL13385495

CC(C)Nc1nc(-c2nc3ccccc3s2)cc(Cl)c1-c1c(F)cccc1Cl

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 4/20 0.40
MEN1 O00255 3/20 0.40
KMT2A Q03164 3/20 0.40
NPC1 O15118 2/20 0.40
PTGES O14684 1/20 0.40
MAPT P10636 4/20 0.39
PAX8 Q06710 1/20 0.39
NOD2 Q9HC29 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
RECQL P46063 1/20 0.39
MGLL Q99685 2/20 0.38
SMN1; SMN2 Q16637 2/20 0.37
TP53 P04637 1/20 0.37
P2RY6 Q15077 1/20 0.36
LMNA P02545 2/20 0.36
IGF1R P08069 1/20 0.36
SRC P12931 1/20 0.36
KDR P35968 1/20 0.36
EPHB4 P54760 1/20 0.36
TEK Q02763 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13385499 0.84 RAB9A (0.39) RAB9AMEN1KMT2ANPC1PTGES
SCHEMBL13385412 0.82 RAB9A (0.43) RAB9AMEN1KMT2ANPC1MAPT
SCHEMBL13385491 0.80 CYP1A1 (0.36) PTGESSRC
SCHEMBL13385481 0.78 CCR1 (0.43) MEN1KMT2ANPC1MAPTL3MBTL1
SCHEMBL13385489 0.77 NR4A2 (0.38) RAB9AMEN1KMT2ANPC1PTGES
SCHEMBL3276721 0.76 BTK (0.34) PTGESMAPTL3MBTL1SMN1; SMN2LMNA
SCHEMBL13404664 0.71 CHRNB2 (0.31)
SCHEMBL13385418 0.70 ACLY (0.38) MEN1KMT2ASMN1; SMN2LMNAKDM4E
SCHEMBL13385494 0.69 NR4A2 (0.37) MEN1KMT2APTGESMAPTKDM4E
SCHEMBL13385465 0.69 JAK2 (0.41) MEN1KMT2ANPC1L3MBTL1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7695728-B2 2-substituted pyridines, processes for their preparation and their use for controlling harmful fungi BASF AKTIENGESELLSCHAFT (DE) 2010-04-13 US disclosed
EP-1761516-B1 2, 4, 5, 6-SUBSTITUTED PYRIMIDINES, METHOD FOR THE PRODUCTION AND USE THEREOF FOR COMBATING PARASITIC FUNGI BASF AG (DE) 2007-11-28 EP disclosed
US-20070259919-A1 2-Substituted Pyridines, Processes for their Preparation and Their Use for Controlling Harmful Fungi BASF AKIENGESELLSCHAFT (DE) 2007-11-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070259919-A1 2-Substituted Pyridines, Processes for their Preparation and Their Use for Controlling Harmful Fungi CYP4X1, CYCS, CYP2S1 RAB9A 1411/4885MEN1 594/4885KMT2A 2279/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.